Zynerba Pharmaceuticals Inc (ZYNE) stock has gained 62.93% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 67 out of a possible 100.
That score is influenced by a fundamental score of 95. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of 22.083. This means analysts expect the stock to rise 230.58% over the next 12 months. ZYNE's score also includes a short-term technical score of 84. The long-term technical score for ZYNE is 20.
Click Here to get the full Stock Score Report on Zynerba Pharmaceuticals Inc (ZYNE) Stock.
What's Happening with ZYNE Stock Today
Zynerba Pharmaceuticals Inc (ZYNE) stock is higher by 3.09% while the S&P 500 has gained 0.08% as of 9:55 AM on Tuesday, Dec 17. ZYNE has gained $0.20 from the previous closing price of $6.48 on volume of 431,185 shares. Over the past year the S&P 500 has gained 25.46% while ZYNE has gained 62.93%. ZYNE lost -$1.50 per share in the over the last 12 months.
